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ABSTRACT 
The first innate immune cells, most importantly for this thesis macrophages, microglia and 
eosinophils, were described more than 100 years ago and only now do we begin to 
understand more about their development, functions and properties.  
So while elimination of pathogens through phagocytosis (macrophages/microglia) or 
degranulation (eosinophils) were long considered as their main functions, research during 
the last decades has made it clear that innate immune cells do much more than maintain 
homeostasis in an organism. 
Monocytes were considered the progenitors of all macrophages, migrating from the 
bloodstream into tissues in order to colonize them. A groundbreaking discovery changed 
our view of tissue macrophage development, proving that they are established during 
embryonic development and that they maintain themselves during homeostasis in tissues 
without input from circulating monocytes. Conversely, monocyte-derived macrophages 
primarily respond to pathogens or injury. Eosinophils were for a long time disregarded to 
have major functions in diseases other than allergies or parasitic infections. However, we 
now know that eosinophils not only play important roles in many diseases, including 
cancer, but also during homeostasis.  
In this thesis I describe how, in the event of significant loss of tissue macrophages, a tissue 
can be repopulated by rapid proliferation of resident cells in addition to infiltration from 
monocytes from the periphery. I have thus primarily studied microglia in the CNS niche 
under both homeostatic conditions and during disease states.  
Our work identified TGF-β as a major signaling pathway involved in niche homeostasis 
and macrophage functional integration into the CNS. Loss of TGF-β signaling or an 
inability to respond to it led to deregulation of microglial function and infiltrating 
macrophage function, causing spontaneous initiation of a fatal motor disease characterized 
by demyelination and damage to neurons.  
We further established a role for eosinophils in a mouse model of Glioblastoma multiforme 
brain tumors, in which depletion of eosinophils led to significantly longer survival of 
tumor-bearing mice, which is in contrast to the current belief that macrophages are the most 
important and major infiltrating immune cell in most solid tumors. As a last approach, we 
used siRNA-loaded nanoparticles to reduce target gene expression of importance in tumor 
development in a mouse model of melanoma. Targeted delivery of therapeutic agents is one 
of the main obstacles in the treatment of cancer. Nanoparticles can be engineered to 
specifically target tumor cells or cells in the tumor vicinity and can be loaded with virtually 
any siRNA, without majorly affecting healthy cells and tissue. Using two delivery systems 
we demonstrated feasibility and efficacy of this approach. 
In summary, in this thesis I highlight the importance of myeloid immune cells in health and 
disease and how targeting them could be of potential therapeutic interest in the future. 
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1 INTRODUCTION 
1.1 INNATE IMMUNE SYSTEM 
Innate immunity was first introduced in 1989 by Charles Janeway Jr., who suggested a 
general theory of innate immune recognition by mechanisms of pattern recognition, and 
proposed that the innate immune system controls the adaptive immune system.  
In defense against pathogens the innate immune system is the first line of defense and it is a 
semi-specific system to keep an organism in homeostasis1. The major constituents include 
surface barriers (most importantly the skin), humoral defense (macromolecules found in 
extracellular fluids) and cellular defense (innate leukocytes)2. 
External structures present the first barrier for an invading pathogen, isolating the internal 
environment from external influences and preventing the spread of microorganisms and 
infection. Epithelial cells connected by tight junctions form complex structures throughout 
the organism to prevent pathogens from entering. Is this structure damaged, for example by 
mechanical forces or insect bites, pathogens are able to enter the organism and the second and 
third barriers will come into play.  
Humoral immunity is commonly referred to as the second barrier of innate immunity and 
comprises of macromolecules found in extracellular fluids. Many different substances have 
been discovered over the years, with the complement proteins first being discovered by Hans 
Buchner (1890) and Paul Ehrlich (1892). These are substances in the serum capable of killing 
pathogens through opsonization, formation of pores in the membrane (membrane attack 
complex) and induction of an inflammatory response, leading to lysis of the pathogen. Other 
humoral components are for example cytokines (which mediate communication between 
immune cells), opsonins (that coat outer membranes of foreign substances and enhance 
phagocytosis), anti-toxins (neutralize toxins produced by invading bacteria) and antibodies 
(part of the adaptive immune response). 
Cellular innate immunity comprises of various different cell types and is considered the third 
line of defense of the innate immune system. Innate leukocytes include γδ T-cells, natural 
killer cells, mast cells, basophils and eosinophils, as well as phagocytic cells including 
neutrophils, dendritic cells and monocytes/macrophages. All these different cell types 
function within the innate immune defense by identifying and eventually eliminating 
pathogens that can cause infections. Innate leukocytes can move freely, as they are 
commonly not associated with a specific tissue or organ, and can therefore easily detect, 
interact and clear cellular debris, pathogens or other foreign particles3,4.  
In this thesis I focus on two innate leukocytes, macrophages and eosinophils, and describe 
their development and their role in health and disease. 
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1.2 TISSUE RESIDENT MACROPHAGES 
Ilya Metchnikoff first discovered macrophages in the late 19th century. Metchnikoff, who is 
now considered to be the father of modern immunology, discovered phagocytic cells in his 
studies of frogs and starfish.  
“I rather believe that the essence of an inflammation lies in the phagocyte attack of solid 
pathogenic substances, be it a weakened or dead cell, a bacterium or any other foreign 
body.” Ilya Metchnikoff, 1883 
This sentence from his 1883 publication distinctly places phagocytes as the major players in 
defense against pathogens in a multicellular organism. Phagocytic cells are conserved 
among a huge number of species, highlighting their importance. The discovery of 
phagocytosis by Ilya Metchnikoff was awarded with the Nobel Prize in Physiology and 
Medicine in 19085,6. 
A lot of research has been conducted during the last decades on the origin of macrophages. 
One of the major influencers in the field of macrophage biology was Ralph van Furth. He 
proposed in the 1960s that all tissue macrophages originate and are replenished from 
circulating monocytes in the blood, coining the term ‘mononuclear phagocyte system 
(MPS)’7. However, with advancement in genetic techniques, studies performed in recent 
years came to a different conclusion and challenged the traditional MPS that van Furth 
characterized. It is now known that tissue macrophages are actually established during 
embryogenesis and persist in adulthood, without (or with limited) input from circulating 
monocytes8,9,10,11,12 and that circulating monocytes can, in addition, differentiate into 
macrophages upon inflammatory stimulation39. 
1.2.1 Development of Tissue Resident Macrophages 
Tissue resident macrophages have crucial functions during development, tissue homeostasis 
and resolution of inflammation and already develop during the early stages of 
hematopoiesis in the embryo. The first stage, also called primitive hematopoiesis, develops 
from the posterior plate mesoderm in the blood islands of the extra-embryonic yolk sac at 
around E7.0, giving rise to primitive erythroblasts, megakaryocytes and macrophages13. 
These early macrophages are independent of the transcription factor MYB, but rely on PU.1, 
which is in contrast to later macrophages that develop during definitive hematopoiesis. The 
pattern of macrophage differentiation is distinctive in that they do not go through a monocyte 
intermediate stage, which is characteristic for adult bone marrow-derived macrophages14. The 
second stage, the ‘transient definitive stage’ of hematopoiesis, leads to the formation of 
hematopoietic progenitors called erythro-myeloid precursors (EMPs), which arise from the 
yolk sac hemogenic endothelium between E8.0 and E8.5. These EMPs can develop into 
erythroid and myeloid cells, but do not have the potential to develop into lymphoid cells15. 
EMPs migrate to the fetal liver where they expand in numbers and differentiate into 
different cell types, including monocytes.  
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After a full blood circulation is developed in the embryo the third stage of hematopoiesis, 
the definitive stage, takes place (E10.5). A new wave of hematopoietic progenitors arises 
from the intraembryonic hemogenic endothelium in the aorta-, gonads-, mesonephros- 
region16,17. These precursors then colonize the fetal liver and the fetal bone marrow, 
eventually giving rise to adult bone marrow hematopoietic stem cells. In the embryo the 
fetal liver will become the major hematopoietic organ, containing progenitors of different 
origins and different potentials for differentiation. Together, these then will give rise to a 
functioning immune system.  
Our understanding of macrophage development has drastically changed since van Furth 
proposed the MPS in the 1960s. It is now known that monocytes have no major 
contribution to most tissue macrophage pools (neither during homeostasis nor during 
inflammation), that adult tissue macrophages are derived from embryonic precursors that 
already seed in their specific tissues before birth, and that tissue macrophages maintain 
themselves in adulthood by self-renewal14.  
Embryonically-derived tissue macrophages require a mechanism that allows them to 
replenish old or apoptotic macrophages during adult life. On the one hand this could occur 
through tissue resident stem cell-like populations with a potential for asymmetric division 
or, conversely, through differentiated macrophages that have self-renewal potential. 
Evidence for the first scenario is currently lacking, but different fate mapping studies 
suggest that tissue macrophages can switch between terminal differentiation and 
proliferation, retaining the macrophage population in homeostasis. This self-renewal of 
tissue macrophages significantly differs from stem cell self-renewal since it results in the 
formation of two daughter cells that are identical, instead of asymmetrical division that 
takes place in stem cells. Self-renewal of tissue macrophages is dependent on CSF1 and 
CSF2 and is driven by the transcription factors MafB and cMaf18,19,20. 
Evidence for the ‘revised’ mononuclear phagocyte system came from various different fate 
mapping studies and simple observations. For example, monocytopenic animals (which 
have a reduced number of circulating monocytes in their blood) do not exhibit any 
differences in their tissue macrophage compositions, suggesting that monocyte input is not 
necessary for tissue macrophage renewal20. In addition, it was observed that in the absence 
of hematopoietic stem cells (HSC), yolk sac progenitors are still capable of giving rise to 
the main tissue resident macrophage populations in the spleen, the pancreas, the liver, the 
brain, the skin and the lung. Some tissue macrophage populations (lung, kidney) are of 
‘chimeric’ origin, meaning they arise from HSC and yolk-sac progenitors9.  
Fate mapping studies make use of the fact that during embryonic development the 
expression of transcription factors differs between cells, which makes it possible to 
genetically label cells and all their progeny, either constantly (Cre) or with inducible 
(CreER) systems. For example, yolk-sac-derived macrophages develop independently of 
the transcription factor MYB, whereas definitive HSC-derived macrophages are dependent 
on this factor for their development and differentiation6,9.  
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This knowledge can be used to track cells that are MYB+ or MYB-, respectively, at certain 
time points during development and into adulthood, making it possible to determine the 
origin of various adult cell populations.   
1.2.2 Generic and Tissue Specific Functions of Macrophages 
Macrophages are an essential part of the innate immune system and act as guards in tissues 
and the whole organism. They are specialized phagocytes and antigen presenting cells, 
neutralizing pathogens and communicating with other parts of the innate as well as adaptive 
immune systems to mount powerful responses against invaders. Tissue macrophages are 
mostly stationary cells that monitor their immediate environments using different sensory 
molecules such as scavenger receptors, pattern recognition receptors (for example Toll-like 
receptors (TLRs), RIG-I-like receptors, C-type lectin receptors and Nod-like receptors), 
nuclear hormone and cytokine receptors as well as adhesion molecules. 
The ‘guard’ function of tissue macrophages is a universal feature of the macrophage cell, 
with only minor adjustments needed depending on the particular tissue in question. Even 
though macrophages look morphologically similar in all tissues they display highly distinct 
and characteristic gene expression signatures and epigenetic signatures. This means that, 
beyond their unifying functions, tissue macrophages have specific tasks associated with the 
homeostasis of the particular tissue of residence21,22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Examples of tissue macrophages and their discovery. Kupffer cell (blue), Microglia 
(pink), Monocyte (blue-red), Osteoclast (yellow), Langerhans cell (brown). 
  9 
In the lung, for example, alveolar macrophages are continuously exposed to microorganisms, 
pollutants and dust from the air we breathe. A major tissue-specific function of alveolar 
macrophages is to tolerate inhaled harmless stimuli, while preserving the ability of mounting 
an immune response against opportunistic pathogens. Alveolar macrophages are involved in 
acute immune responses and tolerance induction and clear excessive surfactant from the 
lungs by phagocytosis23,24. 
Macrophages in the liver, also called Kupffer cells, are specialized in detoxification and iron 
and cholesterol recycling. They do so by filtering the blood and therefore need to be highly 
phagocytic and have a high lysosomal activity. Kupffer cells form a barrier for pathogens to 
enter the systemic circulation and are excellent capturers of antigens and presenters to the 
environment25. 
Splenic macrophages reside in two different sites of the spleen. Red pulp macrophages 
(RPMs) that reside in the red pulp are specialized in uptake of hemoglobin and scavenging of 
senescent or damaged erythrocytes and recovering iron from these cells. Marginal zone 
macrophages are located in the white pulp of the spleen together with marginal metallophilic 
macrophages and clear pathogens from the systemic circulation as well as dead cells and 
debris26,27. 
 
1.3 MONOCYTE DERIVED MACROPHAGES 
Monocytes are key players during inflammation and pathogen challenge. Monocytes are a 
highly plastic population of cells that can complement the classical tissue resident 
macrophage upon demand (during inflammation or infection) and exist as two major 
populations in humans and mice.  
‘Classical’ monocytes have a half-life of about 20 hours in the blood, and ‘non-classical’ 
monocytes are longer lived and can exist over several days. Both populations are primarily 
present in the blood circulation, the spleen, the lung and the bone marrow28,29.  
1.3.1 Development of Monocytes 
Monocytes are blood mononuclear cells with bean-shaped nuclei that are constantly 
produced in adults and arise from definitive HSCs. They are a conserved population of 
leukocytes in both mice and humans.  
HSCs first develop into proliferative precursor cells, previously called ‘monoblasts’ and 
‘pro-monocytes’30,31 and nowadays referred to as ‘multipotent progenitors’. Multipotent 
progenitors (MPP) develop further into either ‘common lymphocyte progenitors’ (CLP) 
(which will give rise to T- and B-cells) or ‘common myeloid progenitors’ (CMP). The 
CMP lineage subdivides further into MEP (‘megakaryocyte-erythrocyte progenitor’), which 
give rise to platelets and erythrocytes, and a GMP (‘granulocyte-macrophage progenitor’) 
branch32,33.  
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GMP can either directly differentiate into basophils, eosinophils or neutrophils or 
differentiate into the ‘monocyte-macrophage DC progenitors’ (MDP), which have the 
potential to give rise to a ‘common DC progenitor’ (CDP) as well as ‘common monocyte 
progenitors’ (cMoP).  
CDPs can only commit to become a dendritic cell and do not develop into monocytes or 
macrophages34,35. Monocytes solely derive from cMoP, which was identified in 2013 by 
Hettinger et al.36. The processes and transcription factors determining whether MDP decide 
to become a CDP and eventually give rise to dendritic cells or become a cMoP and give rise 
to monocytes are as yet not well understood, but it is clear that monocytes, macrophages 
and DCs are developmentally closely related and share similar functions in the body.  
The development and survival of monocytes are entirely dependent on colony-stimulating 
factor 1 (CSF1 or MCSF), and mice that lack either CSF1 or its receptor CSF1R (CD115) 
are severely monocytopenic37,38.  
  
Figure 2: Classic model of hematopoiesis. HSC-Hematopoietic stem cell, MPP-multipotent progenitor, CLP-common lymphoid 
progenitor, CMP-common myeloid progenitor, MEP-megacaryocyte-erythrocyte progenitor, GMP-granulocyte-macrophage 
progenitor, MDP-monocyte-macrophage DC progenitor, cMoP-common monocyte progenitor, CDP-common DC progenitor. 
  11 
Monocytes are described by their morphology, characteristic gene signatures and miRNA 
signatures and are currently classified into two main populations: ‘classical’ or 
‘inflammatory’ monocytes and ‘non-classical’ monocytes.  
In mice, ‘classical’ monocytes are referred to as CD11b+ Ly6Chigh CCR2+ CX3CR1mid 
CD62L+ and CD43low, whereas ‘non classical’ monocytes can be identified as CD11b+ 
Ly6Clow CCR2- CX3CR1
high CD62L- and CD43high 39,40. In humans, these cells are referred to 
as CD14high CD16- (‘classical’) and CD14low CD16+ (‘non-classical’)41. 
1.3.2 Functions of Monocytes and Monocyte Derived Macrophages 
Classical Monocytes:  
Classical monocytes circulate in the blood during homeostasis but can be quickly recruited 
upon inflammatory stimuli to a site of injury or inflammation and initiate an inflammatory 
reaction necessary to clear pathogens or repair injury. After extravasation from the 
bloodstream through the vessel wall, monocytes enter the tissue and differentiate into 
mononuclear phagocytes, mostly macrophages but also DCs.  
Upon differentiation, monocyte-derived macrophages start upregulating genes necessary for 
antigen processing and phagocytosis, as well as T-cell co-stimulation. Depending on the 
tissue that monocytes infiltrate they can additionally upregulate genes needed for specific 
tissue functions a macrophage has in that tissue14,20,42.  
CCR2 and its ligands CCL2 and CCL7 (MCP3) are the major chemokines involved in 
monocyte recruitment to tissues. CCR2 is only expressed on a limited number of cell types, 
while, in contrast, all cells can express CCL2 upon stimulation by inflammatory signals. 
Although it is known that CCL2 expression is induced during inflammation, its exact 
mechanism of action remains unknown. One model suggests that CCL2 binds to 
glycosaminoglycans expressed in tissues to establish a gradient that guides monocytes to the 
site of inflammation or injury43,44. Once monocytes are attracted they have to ‘squeeze’ 
through the vessel wall (diapedesis) to access the tissue. In order to do so, monocytes adhere 
to the vessel wall and traffic through the endothelium. Monocytes will slow down in the 
bloodstream and start rolling along the vessel wall with the help of integrins (VLA4, LFA1, 
VCAM1) and selectins (L-selectin, P-selectin, E-selectin) as the major adhesion molecules 
involved, eventually coming to a stop by binding to chemokines (CCL5, CXCL4 and 
CXCL5). The cells will then be able to transmigrate through the endothelial vessel wall in an 
ICAM1-, MAC1-dependent manner and enter the tissue42,45,46.  
Once in the tissue, monocytes mediate antimicrobial actions. One of the best-studied 
infections is caused by Listeria monocytogenes. Upon infection with this Gram-positive 
bacterium, monocytes are recruited to the liver and the spleen, the two major sites of 
infection, in a CCR2-dependent manner and differentiate into macrophages that start 
producing TNF (tumor necrosis factor) and iNOS (inducible nitric oxide synthase), critical in 
fighting the infection47,48.  
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During later stages of the disease, Listeria selectively targets and kills Kupffer cells in the 
liver, which are then replaced by recruited monocyte-derived macrophages49.  
It is now established that tissue macrophage populations are maintained without input from 
monocytes during homeostatic conditions and that monocytes can be recruited to tissues and 
become monocyte-derived macrophages upon infections. But exceptions to this rule exist as 
in certain tissues monocytes contribute to the pool of tissue macrophages, most notably in the 
intestine. Classical monocytes (Ly6Chi) continuously replace the macrophage populations in 
the intestine, significantly in the lamina propria9,10,11. This might be due to macrophage 
exposure to the microbiota in the intestines, supported by the finding that embryonic 
macrophages in the intestine are replaced by monocyte-derived macrophages during the first 
couple of weeks after birth, at the same time when bacteria start colonizing the gut50.  
Other macrophage pools that are slowly replaced by circulating monocytes are found in the 
testicles51, the dermis52, the choroid plexus of the brain53, the peritoneal cavity54 and the 
exocrine pancreas55. It is so far unclear if this replacement is triggered by the constant loss of 
macrophages or is due to that a niche is opened up for monocytes to occupy.  
Non-classical monocytes: 
The functions of non-classical monocytes are still under investigation but it has been shown 
that they actively patrol blood vessels for damage, and repair any damage they encounter. In 
addition it is thought that due to their location, non-classical monocytes might be the first 
monocytes to enter tissues upon inflammatory stimuli and are also capable of differentiating 
into macrophages56,57. Ly6Clo monocytes are generated from Ly6Chi monocytes in the 
circulation through a Ly6Chi intermediate which is dependent on the transcription factor 
C/EBPβ 10,14,58. 
 
1.4 MICROGLIA 
Microglia, the macrophages of the brain and spinal cord, are the only resident hematopoietic 
mesodermal-derived cell type in the central nervous system parenchyma59. Even though 
microglia were already visualized in 1880 by Franz Nissl, who developed the Nissl staining 
for different neural cells including microglia, it took until 1919 for them to be fully 
recognized as being ‘microglia’ by Pío del Río Hortega, who is now considered the ‘father of 
microglia’ due to his research on microglia responses during brain injury60. Microglia account 
for 10-15% of all cells in the brain and are crucial in maintaining homeostasis in both the 
brain and spinal cord61. Microglia constantly monitor the CNS for plaques, damaged neurons 
or synapses and pathogens62. They are among the most sensitive cells in an organism due to 
unique potassium channels that respond to the smallest changes in extracellular potassium 
that leads to a reaction of the microglial cell63.   
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1.4.1 Development of Microglia 
For many years it was believed that adult microglia are established through embryonic and 
perinatal hematopoietic waves64,65. In 2010, Ginhoux et al.8 provided proof that microglia 
develop from primitive myeloid progenitors that arise before embryonic day 8 (E8). The first 
evidence was gained by reconstituting sub-lethally irradiated C57BL/6 CD45.2+ newborn 
mice with hematopoietic cells isolated from CD45.1+ congenic mice. Approximately 30% of 
circulating leukocytes were of donor origin after 3 months, whereas 95% of microglia were 
still CD45.2+, suggesting that the microglial pool is not replenished by circulating leukocytes 
but is of host origin8. This is in contrast to previous reports in rats where monocytes were 
reported to differentiate into amoeboid microglia in the corpus callosum66 or upon brain 
injury67.  
Previous to this 2010 study chimeric animals were used to study the origin of microglia. 
Different results were reported, some in favor of a hematopoietic precursor cell60,68 and some 
against69,70. Ginhoux et al. confirmed both scenarios using bone marrow chimeras as well as 
parabiotic animals. In order to transplant new bone marrow mice need to be irradiated, which 
damages the blood brain barrier (BBB), making it possible for bone marrow cells to pass the 
BBB and enter the brain. This leads to differentiation of hematopoietic precursors into 
microglia upon infiltration of the CNS69,70,71. Conversely, in parabiotic mice, which share a 
blood circulation, the microglial pool was only replenished to a minimal extent by 
hematopoietic precursor cells, whereas other tissue macrophages were replaced by up to 30%, 
even after 12 months of parabiosis8.  
Using a fate mapping approach, Ginhoux et al. further studied the origin of microglia during 
development. Using an inducible runt-related transcription factor 1 (Runx1) CreER system 
they were able to label Runx1-expressing cells at E7.0, which is prior to definitive 
hematopoiesis in the mouse embryo. Using this system they could convincingly show that 
Runx1-expressing yolk-sac-derived macrophages persist into adulthood as microglia6,8.   
1.4.2 Functions of Microglia in Homeostasis and Disease 
Microglia are commonly referred to as ‘brain macrophages’ due to many similar functions to 
other tissue macrophages, but they are unique when it comes to their origin, their homeostatic 
phenotype and their tight regulation by the CNS microenvironment. Microglia are not only 
important for the elimination of pathogens and resolving of inflammation and injury, they 
also have a major role in regulating brain development and maintaining neuronal networks72. 
Microglia continuously monitor the brain during homeostasis by extending and protruding 
their branches and processes. These ‘resting’ or ‘ramified’ microglia cover huge areas and 
make contact with neurons, astrocytes and blood vessels in order to ensure functionality of 
synapses and that there are no pathogens or dead cells that can threaten CNS 
homeostasis73,74,75. If microglia encounter an injury, inflammatory event or pathogens, they 
become activated (amoeboid morphology).  
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Their cell bodies swell and their processes shorten, making them highly activated pro-
inflammatory cells capable of very efficient phagocytosis and elimination of intruders76. Just 
like macrophages, microglia express different pattern recognition receptors (PRR) that sense 
pathogens via pathogen-associated molecular patterns (PAMPs) and danger via danger- 
associated molecular patterns (DAMPs), for example Toll-like receptors (TLR 1/2 and 
TLR4), NOD-like receptors (NLRP3 inflammosome) and scavenger receptors that enable 
them to perform phagocytosis e.g. CD36, MARCO and SR177,78. In addition, microglia 
express various chemokine receptors, most prominently CX3CR1 and CX3CR4, as well as 
integrins (CD11b, CD11c) that help control microglial positioning and movement in the 
CNS79,80. Microglial activation is regulated by immune receptors, the best studied being 
TREM2 (triggering receptor expressed on myeloid cells 2) and CD3381,82 and the inhibitory 
receptors SIRPA as well as CD200R183,84.  
Microglia aid in the formation of neuronal networks during development by guiding other 
glial cells and neurons85. In adults, microglia comprise a major part of the neurogenic niches 
in the subventricular zone (SVZ) and the subgranular zones (SGZ) in the dentate gyrus, 
which produce neurons that accommodate the olfactory bulb and hippocampus. Microglia are 
attracted to these neurogenic niches by factors released from apopototic neurons (f.ex. ATP) 
and CXCL1286. In adults, microglia are crucial for shaping synaptic spines by phagocytosing 
retired dendritic spines, a process called ‘synaptic stripping’87,88. Synapse plasticity and 
strength are regulated, in part, by pro-inflammatory factors released by microglia as well as 
CX3CR1-CX3CL1 interactions. Mice lacking CX3CR1-CX3CL1 have impaired connectivity 
and afferent synaptic inputs in the hippocampus89.  
Taken together, microglia serve on the one hand as the macrophages of the brain, combating 
pathogens and phagocytosing dead cells and debris, and on the other hand they aid brain 
development by helping form neuronal networks and playing a crucial part in the adult in 
synaptic pruning – this unique homeostatic functions distinguish microglia from other tissue 
macrophages in the body. In addition, microglia display a unique transcriptional profile with 
many genes that do not overlap with other resident tissue macrophage genes.  
1.4.3 Experimental Depletion Models 
Monocyte/Macrophage Depletion Models: 
Depletion of macrophages and monocytes is nowadays a commonly used method to study 
niche signals defining tissue macrophages or to elucidate the role of macrophages in various 
diseases. The first macrophage depletion technique was introduced in the 1980s by van 
Roijen, who used clodronate-encapsulated liposomes to deplete circulating monocytes90. A 
more targeted approach to experimentally deplete Ly6Chi monocytes is through using 
antibodies against CCR2, or CCR2-/- mice in which Ly6Chi monocytes are prohibited from 
leaving the bone marrow and entering the circulation91,92. The generation of the CD11b-DTR 
mouse93, in which upon diphtheria toxin (DT) administration macrophages can be efficiently 
depleted at chosen time points, made it possible to study macrophage ablation in even more 
detail.  
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In these mice the transgenic expression of the human DT receptor (DTR) confers sensitivity 
to DT and permits ablation in vivo when DT is injected, due to the fact that the mouse DT 
receptor only binds DT poorly compared to the human counterpart93,94.  
Microglia Depletion Models: 
Clodronate liposomes do not ablate the microglial pool because they do not cross the BBB. In 
order to overcome this obstacle to study microglia depletion, various groups injected 
clodronate liposomes intracerebroventricularly (i.c.v), leading to efficient depletion of the 
microglial pool95,96,97. A major step forward in the field of microglia depletion was the 
development of the CD11b-HSVTK mouse, which expresses the herpes-simplex virus 
encoded suicide-gene thymidine kinase under the CD11b-promoter98. About 95% of 
microglia are depleted upon gancicolvir injection using an osmotic pump in this system99. 
However, ganciclovir treatment becomes toxic after prolonged administration of 4 weeks. 
Upon withdrawal of ganciclovir, microglia are entirely exchanged by peripheral myeloid 
cells100,101.  
To allow a more specific depletion of microglia, Cx3cr1Cre mice were developed. When bred 
with Rosa26DTR mice, microglia are depleted without affecting CX3CR1+ bone marrow 
cells102,103,104,105  upon Tamoxifen and diphtheria toxin administration. Since microglia require 
CSF1R for their development (CSF1R-/- mice are born without microglia106), inhibiting this 
receptor pharmacologically leads to 99% microglia depletion within 21 days, making it a 
faster approach for efficient microglial depletion8,106,107; however, peripheral macrophages are 
also depleted, making the genetic model more favorable for specific targeting of microglia.  
 
1.5 EOSINOPHILS 
Paul Ehrlich was the first to describe eosinophils in 1879 after noticing their potential to be 
stained by acidophilic dyes, hence the term ‘acidophiles’. Even though eosinophils were 
described a long time ago, their functions still remain elusive to a large extent108. Eosinophils 
differ in morphology, cell-surface receptor expression and intracellular content among 
species, but are conserved in all vertebrates109. In human blood, mature eosinophils only 
circulate in small numbers (400 cells per mm3 blood) during homeostasis, while their 
numbers can increase rapidly upon infection when eosinophils leave the bone marrow upon 
certain stimulation110. Eosinophils have mostly been studied in parasitic infections and 
allergic reactions such as asthma111,112,113, but it is becoming clear that they have implications 
in many more diseases, including cancer114,115,116,117.   
1.5.1 Development of Eosinophils 
Eosinophils develop in the bone marrow from a hematopoietic precursor, the GATA-1+ 
common myeloid progenitor (CMP). After progressing through the pre-granulocyte 
macrophage progenitor stage (Pre-GMP) they further differentiate into GATA-1+ granulocyte 
and macrophage progenitors (GMP, also known as eosinophil/mast cell progenitors EoMP). 
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IL-33 regulates further development and expansion into eosinophil precursors as well as 
inducing a currently unidentified cell that starts producing IL-5 that is required for final 
eosinophil maturation118. Three transcription factor families, GATA-1, PU.1 and C/EBP, 
define eosinophil lineage specification. Mice lacking the high affinity GATA-1 binding site 
do not have eosinophils, making it the most important transcription factor involved in 
eosinophil development119. Even though other cell lineages are also GATA-1+ (mast cells, 
megakaryocytes, erythroid cells), it appears that GATA-1 has specific functions in 
eosinophils, very likely mediated by a palindromic GATA site. This specific GATA site is 
present in the downstream GATA-1 promoter region, as well as regulatory regions of 
eosinophil-specific genes (CCR3, MBP, IL-5Ra) and it is responsible for eosinophil specific 
gene expression120,121,122.  
IL-5 is necessary for selective differentiation of eosinophils, their release from the bone 
marrow and their maturation123. Over-expression of IL-5 in transgenic mouse models leads to 
extensive eosinophilia124,125,126, whereas deletion of the IL-5 gene leads to a significant 
reduction of eosinophil numbers in the blood and lungs, even after allergen challenge127,128. In 
humans, disease-associated eosinophilia is also regulated to a major extent by IL-5 and 
treating these patients with humanized anti-IL-5 antibodies can drastically reduce eosinophil 
numbers in the blood and to a certain extent in the lungs of patients129, 130,131.   
1.5.2 Functions of Eosinophils in Homeostasis and Disease 
Eosinophils were for a long time considered as end-stage effector cells involved in defense 
against pathogens132. It is now known that eosinophils also have many more functions during 
development and other biological processes, ranging from mammary gland development133, 
viral infections134, estrus cycling135, allergic responses, neoplasia136 to involvement in organ 
transplantation137.  
Eosinophils in Homeostasis: 
Eosinophils are found abundantly in the female reproductive tract, with numbers increasing 
during the estrus cycle. IL-5 attracts eosinophils to the uterus, but it was shown that some 
eosinophils are IL-5 independent since mice lacking IL-5 have a residual population of 
eosinophils in the uterine stroma135. Ovarian hormones influence eosinophil chemoattractants 
(eotaxin-1, RANTES) leading to influx of eosinophils. Mice lacking eotaxin-1 do not have 
uterine eosinophils and have a two-week later onset of estrus as well as a delayed age of 
parturition138,139.  
Eosinophils are also implicated in postnatal mammary gland development. Eotaxin-1 mRNA 
levels are increased during mammary gland formation, correlating with eosinophil influx into 
the tissue. Mice lacking eotaxin-1 have a deficiency in terminal end bud formation and 
reduced branching complexity of the ductal tree140.  
Recruitment of eosinophils to the cortico-medullary region of the thymus during the neonatal 
period is also regulated by eotaxin-1. A second wave of eosinophils, expressing high levels of 
MHCII, infiltrates the thymus at a later stage, coinciding with the commencement of thymic 
involution141. 
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Eosinophils in Immune Regulation: 
Eosinophils perform many functions in immune regulation such as antigen presentation142,143 
and release of cytokines and lipid mediators to mediate inflammatory responses112,144. 
Eosinophils are capable of processing and presenting antigens from various pathogens, 
including microbes, parasites, and viruses144, promoting proliferation and polarization of 
CD4+ T-cells. Eosinophil antigen presentation capabilities have mostly been studied in vitro, 
with discrepancies in the results, most likely due to different eosinophil isolation techniques 
used145. Eosinophils secrete cytokines (IL-2, IL-4, IL-6, IL-10, IL-12) that activate T-cells 
and mount an effective immune response to invaders, again demonstrating a tight relationship 
between these two cell types146. In addition, eosinophils impact secretion of IL-4, IL-5 and 
IL-13 by T-cells, cytokines necessary for eosinophil maturation and activation142,143,147.  
Eosinophils and Cancer: 
Many studies in various types of solid cancers (colon cancer 148,149, squamous cell 
carcinomas150, bladder cancer151) have revealed that tumor-associated tissue eosinophilia 
(TATE) has a positive effect on patient survival and outcome. In contrast, TATE in Hodgkin 
lymphoma patients seems to be an indicator for poor prognosis152.  
TATE is mostly observed in necrotic areas of the tumor and eosinophil migration is induced 
by necrotic cells both in vivo and in vitro153,154. Necrotic cells release eosinophil-derived 
high-mobility group box 1 (HMGB1) that binds to RAGE on eosinophils and triggers 
eosinophil degranulation155. 
Tumor cells also produce other cytokines (IL-5, IL-3) and chemokines (eotaxin-1, CCL17) 
that induce eosinophil maturation and migration to the tumor site156. 
Cytotoxic anti-tumor responses are proposed to act through degranulation of eosinophil 
granules, but this is still debated and not well understood. One factor strengthening this 
hypothesis is observations of granule proteins in the tumor vicinity157. A recent study 
determined that eosinophils help to reject cancer by normalizing blood vessels and enhancing 
infiltration of tumor-specific CD8+ T-cells114. Eosinophils may also alter the tumor 
microenvironment to become less immunosuppressive by changing the polarization states of 
macrophages to a more pro-inflammatory type, leading to tumor eradication and longer 
survival114. IL-2 immunotherapy is a common treatment for melanoma and renal cell 
carcinomas. Part of the antitumoral effect of systemic IL-2 therapy is thought to be due to 
degranulation of eosinophils within tumors158,159.  
 
1.6 MALIGNANT GLIOMA 
Primary brain tumors account for about 2% of cancers in the western world and can generally 
be classified as glioma (astrocytoma, oligodendroglioma, ependyomas) or non-glioma 
(menigiomas, pituitary tumors, medulloblastoma). Malignant gliomas account for about 30% 
of all brain tumors and are the most common subtype of primary brain tumors, characterized 
by their highly aggressive, invasive and neurological destructive nature160.  
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Malignant gliomas are considered to be among the deadliest human cancers with 
glioblastoma multiforme (GBM) being the most frequent and aggressive form161. This cancer, 
as with many other human cancers, involves a variety of cellular processes and genetic and 
epigenetic DNA modifications needed to initiate (formation), promote (proliferation) and 
progress (migration)162,163.  
Despite recent advances in glioma biology the median survival has changed little during the 
last decade and only ranges from 12-14.5 months164. Up until now the gold standard of 
therapy has been maximum surgical resection of the tumor mass followed by radiotherapy 
and Temozolomide chemotherapy according to the FDA. 
The first brain tumor surgery was performed in 1884 to much acclaim by Rickman Godlee, 
but soon after the initial enthusiasm faded because it became clear that survival was only 
slightly prolonged using this approach. Thirty years later Harvey Cushing and Percival Bailey 
suggested the first grading scheme for malignant gliomas based on morphological 
appearance. They described the diffuse nature of gliomas, indicating cure of the disease 
through surgery alone was quite impossible. To date, only the invention of chemotherapeutic 
agents that can cross the blood brain barrier (in the early 20th century) has increased the 
median survival of glioma patients by a couple of months from a prior maximum of 12 to a 
maximum survival of 15 months165.  
Since then great progress has been made in the field of immunotherapy and other cancer 
treatments for different kinds of cancers such as breast, lung and prostate cancers, as well as 
for melanomas and leukemias. However, it is stunning how inefficient these approaches are 
in the treatment of malignant gliomas160.  
1.6.1 Grading of Gliomas 
The most commonly used scheme for grading and classification of gliomas was published by 
the World Health Organization (WHO). Gliomas are thus classified according to their line of 
differentiation, being either astrocytic, oligodendroglial or ependymal cells. Astrocytic 
tumors are further classified into pilocytic astrocytoma, astrocytoma, anaplastic astrocytoma 
and glioblastoma. Furthermore, gliomas are graded into classes I to IV depending on their 
degree of malignancy166,167. This grading is related to histological features of the tumor such 
as high cellularity, cellular pleomorphism, mitotic activity, microvascular proliferation and 
necrosis. 
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Table 1: Grading scheme for CNS tumors  
Grade I Tumors are benign and can be surgically cured if resection is possible. 
Grade II 
Slow growing tumors that can be malignant or non-malignant and follow long 
clinical courses. Can recur as higher grade tumors. 
Grade III Malignant tumors, leading to death within a couple of years after diagnosis. 
Grade IV 
Highly malignant tumors, usually unmanageable by surgery, radiotherapy and 
chemotherapy and lethal within 12-15 months. 
In 2016 the new WHO classification of CNS tumors was introduced, using molecular 
parameters in addition to histology to describe the different tumor entities. GBM is now 
classified as being either IDH-wildtype (about 90% of cases, corresponding to primary 
GBM), IDH-mutant (corresponding to secondary GBM) or GBM NOS for which a full 
characterization of the IDH mutation status cannot be performed168,171. 
1.6.2 Glioblastoma multiforme 
About 3 in 100,000 people are newly diagnosed with GBM annually, accounting for more 
than 51% of all gliomas. More than 90% of these cases are primary GBMs that arise from 
normal glial cells through oncogenesis, typically in older patients without any prior signs of 
disease (>62 years). The other 10% are secondary gliomas that originate from lower grade 
tumors (mostly astrocytomas). These secondary gliomas expand distinctly more slowly than 
the primary GBMs and are common in younger patients (<45 years). Secondary GBM 
transforms from low to high-grade tumors within 4-5 years, regardless of prior 
therapy160,169,170. Even though these two subtypes of GBM have different genetic profiles and 
are therefore considered to be two distinct clinical entities, no distinctions are made in terms 
of treatment. However, in terms of prognosis, primary gliomas are considered worse than are 
secondary gliomas. 
  
Figure 3: WHO classification for glioma. Hallmarks of GBM: microvascular proliferation (black arrowhead); 
pseudopalisading necrosis (black arrows). 
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Etiology of GBM: 
Malignant gliomas or GBM are thought to derive from neuroectodermal stem cells or tumor 
progenitor cells168. They are spontaneously occurring tumors associated with a deregulated 
G1/S checkpoint in the cell cycle leading to further mutations in glioma cells (e.g. loss of 
heterozygosity on chromosome 10q, amplification of EGFR, AKT3, FGFR2 and mutations in 
PTEN, TP53 or NF1)171. In rare cases GBM can also occur due to a genetic predisposition; 
for example individuals with tuberous sclerosis172, Turcot syndrome173, multiple endocrine 
neoplasia type IIA174 or neurofibromatosis type I175 were reported to be more prone to 
developing GBM. 
Apart from ionizing radiation, certain chemicals, common mutations and pre-existing genetic 
diseases as etiologic factors, the human cytomegalovirus (HCMV) is also believed to cause 
GBM. This virus encodes different proteins involved in mutagenesis, apoptosis, 
inflammation, angiogenesis and mitogenesis, leading to a dysregulation in key signaling 
pathways such as PDGFR, Akt and STAT3176,177. Single nucleotide polymorphisms (SNP) in 
IL-4Rα (interleukin 4 receptor) and IL-13 genes were also identified as risk factors for the 
development of GBM, and this suggests that tissue inflammation plays a role in the process 
of GBM development178. 
Clinical and Morphological Features of GBM: 
GBM is a tumor of the central nervous system (CNS), most often located in the hemispheres 
or subtentorial in the brain stem and cerebellum179,180. Due to its infiltrative nature it is 
difficult to distinguish the tumor mass from normal brain tissue, making complete surgical 
resection impossible. GBM barely metastasizes to other organs, most likely due to the 
isolated location of the brain and the barrier created by cerebral meninges but also the 
aggressiveness and therefore short course of disease might be a reason 181. 
Clinical symptoms of GBM are very much dependent on the age of the patient, location and 
the size of the tumor and how fast it grows. Clinical signs of the disease include severe 
headaches, dizziness, seizures, increased intracranial pressure and neurological deficits or 
changes in the patients’ mental status182.  
GBM is usually diagnosed using gadolinium-enhanced MRI examination whereby it typically 
presents with irregular contours and strong contrast enhancement around a darker necrotic 
area183 and is morphologically profoundly different from normal brain tissue. The cells are 
small polygonal to spindle shaped with indistinct cellular borders and oval or elongated 
nuclei with multiple nucleoli. Binuclear and multinucleated cells are also present, as are 
lymphocytes, neutrophils, macrophages and necrotic cells184. The most prominent feature of 
GBM is necrotic foci, either in the central area of the tumor or small irregularly shaped 
necrotic foci surrounded by pseudopalisading areas.  
The treatment of GBM comprises maximum surgical resection of the tumor mass, 
radiotherapy and chemotherapy. Due to the complex nature of the tumor, these treatments 
only minimally increase the patients’ life expectancies.  
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GBM tumor cells have a highly infiltrative nature into the surrounding brain tissue and easily 
evade surgical intervention as well as radio- and chemotherapeutic interventions. They do so 
by down-regulating certain tumor suppressor proteins, production of immunosuppressive 
cytokines and up-regulation of DNA repair enzymes185. Chronic inflammation and the 
recruitment of regulatory T-cells as well as myeloid-derived suppressor cells effectively 
interfere with innate and adaptive anti-tumor immune responses186. 
 
1.7 MALIGNANT MELANOMA 
Melanoma is the deadliest form of skin cancer and incidences are rising despite the fact that 
the major cause of melanoma, exposure to the sun and UV radiation, is well described187,188. 
Development of melanoma is not only influenced by the time of exposure, but also the 
patterns of exposure seem to be important187. Even though preventive measures are available, 
most importantly sun protection, only a limited number of people use them. Melanoma is a 
highly treatable cancer, but once it metastasizes prognosis is poor189.  
Etiology and Therapy of Malignant Melanoma: 
Melanoma arises due to genetic mutations in the pigment-producing cells, melanocytes, of 
the skin, the eye, inner ear and leptomeninges. Melanocytes are the only cell type in the body 
producing melanin pigments from tyrosine and cysteine precursors190, a complex biochemical 
mechanism. Due to its complexity, melanocyte intracellular systems, compartmentalization, 
detoxification and repair are prone to damage190.    
Chemotherapy was the first treatment available for malignant melanoma, and even though 
treatment regimens have been improved and different combinations have been tested, overall 
survival was not affected191,192. Although better treatments are on the market, 
chemotherapeutics are still used for palliative treatment of refractive, progressive and 
relapsed melanomas193.  
Immunotherapy is a promising approach to target melanoma due to the fact that melanoma is 
a highly immunogenic cancer194. Already in the 1900s it was noticed that tumors are 
infiltrated by immune cells and are inflammatory hotspots, but only now is this knowledge 
used to design effective therapies195.  
Interferons (IFNs) activate and inhibit certain cell types. T-cells, B-cells, natural killer cells 
and DCs are commonly activated by IFNs, whereas regulatory T-cells and MDSCs are 
inhibited. IFNs can interfere with viral replication but also play an inherent role in 
immunomodulatory, antiangiogenic, antiproliferative and antitumor activities196. Treatment 
with IFN- has an immunomodulatory antitumor effect by inhibiting the proliferation of 
melanoma cells due to a stimulatory effect on MHCI expression on immune cells and 
melanoma cells as well as inducing apoptosis upon certain doses197,198. 
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CTLA-4 and PD-1/PD-L1 are the newest generation of immunotherapeutics for the treatment 
of various cancers, including malignant melanoma. They belong to the class of checkpoint 
inhibitors that block T-cell activation to induce immune tolerance199,200. Blocking these 
checkpoints with antibodies interferes with the inhibitory effects, enhancing the production of 
pro-inflammatory T-cell cytokine production and T-cell expansion201, which infiltrate the 
tumor and attack tumor cells. Many adverse effects have been reported, including dermatitis, 
colitis, drug-related hepatitis, endocrinopathies and neuritis202. Several clinical trials are 
currently investigating combination therapies using checkpoint inhibitors together with 
chemotherapy, radiation therapy or other immunotherapies189. 
Other treatment strategies comprise for example adoptive T-cell therapy (ACT), where 
patients are infused with melanoma specific T-cells (ideally isolated from the patient 
themselves), but the generation of these cells is complicated, expensive and requires a lot of 
time203. Targeted therapies are available, targeting and inhibiting the most commonly mutated 
genes in melanomas, BRAF, MEK, VEGF and PI3K-AKT-mTOR pathway189.  
 
1.8 TUMOR MICROENVIRONMENT  
The close interplay between tumors and their microenvironments was already suggested in 
1889 by Stephen Paget. He postulated in his ‘seed-and-soil’ theory that metastases of one 
type of cancer (seed) is more likely to metastasize to sites similar to the original and 
secondary tumor sites (soil) (Paget 1889). Nowadays it is known that the tumor 
microenvironment is the (cellular) environment in which the tumor exists. This includes 
lymphocytes and inflammatory cells but also blood vessels, immune cells, fibroblasts, as well 
as signaling molecules (for example cytokines and chemokines) and extracellular matrix 
proteins. The tumor interacts with and influences its microenvironment by releasing 
extracellular signals to promote tumor growth, angiogenesis and inducing peripheral immune 
tolerance to escape immune surveillance186,204. Immunosuppressive cytokines such as 
prostaglandin E2, TGF-β and IL-10, among others, are highly expressed in GBM and tumor 
infiltrating T-cells consist of an enriched population of CD4+/CD25+/FoxP3+ regulatory T-
cells (Tregs)205, making the tumor microenvironment even more immunosuppressive. 
Additionally, various tumor stem cells have also been reported to be immunosuppressive206. 
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2 METHODS 
2.1 CRE-LOX SYSTEM 
To better study specific genes and their functions in specific cell types, tools have been 
developed that allow the introduction of mutations into the mouse genome at a certain time 
point, in certain tissues and even in certain cell types207. The Cre/lox site-specific 
recombination technique is the most commonly used tool to generate mouse mutants and 
allows control of gene activity in almost any mouse tissue. This allows the study of gene 
function in more detail and helps develop more sophisticated animal models of human 
disease208. The Cre/lox system is based on the use of a site-specific recombinase Cre 
(cyclization recombination), which catalyzes recombination between two recognition sites, 
loxP (locus of crossing over of bacteriophage P1)209. To delete genes two loxP sites are 
introduced that flank an essential exon of the gene of interest by homologous recombination 
in embryonic stem cells. Cre then excises the targeted exon from the chromosome, generating 
a null allele in all cells that express Cre. Cre can be delivered by crossing mice carrying the 
loxP sites with mice carrying the Cre of interest. To achieve cell-specific or tissue-specific 
gene deletion, a Cre-recombinase that is under the control of a specific promoter is used.  
A major breakthrough in the Cre/lox system was the development of ligand-dependent Cre 
recombinases (CreER) that can be activated by administration of tamoxifen to the animal. 
Using this system, Cre activity can be turned on at any time 210,211. I used this system in 
Paper I214 and Paper II215, studying microglia depletion and deletion of Tgfβr2 in distinct 
cell subsets. 
 
2.2 CX3CR1-DTA MICROGLIA DEPLETION MODEL 
Depletion of microglia is commonly used to study the role of microglia in homeostasis and 
disease. As reviewed in chapter 1.4.3, many different techniques have been developed to 
target microglia, but a major breakthrough was the development of Cx3cr1CreER mice102,103. 
Specific depletion of microglia in these mice is achieved when crossing them with R26DTR 
mice, which have DTR inserted into the ubiquitously expressed Rosa26 locus212. Even though 
microglia are efficiently depleted to up to 80% in these mice, rapid proliferation of microglia 
compensates for the loss of cells104. To overcome this we crossed Cx3cr1CreER mice to R26DTA 
mice 214. Tamoxifen administration in these mice results in almost complete depletion of the 
microglial niche (>95%), yet also in this model repopulation occurs through a combination of 
CNS-resident microglia repopulation and infiltration of Ly6Chi monocytes, distinguishable by 
their expression of F4/80. This model was used to study depletion and repopulation in  
Paper I214 and the role of Tgfβr2 in repopulating cells in Paper II215.  
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2.3 GL261 GLIOBLASTOMA MODEL 
GL261 is a syngeneic mouse model in C57BL/6 mice. Since these mice do not require a 
deficient immune system, the GL261 model is thought to mimic GBM growth and immune 
responses of human GBM more closely than other mouse models. The model was developed 
by Seligman and Shear in 1939, who implanted 20-methylcholantrene pellets into the brain 
parenchyma of mice216,217. GL261 tumors are characterized by their poorly differentiated 
cells with a morphology similar to human GBM cells218,219 and their infiltrating and invasive 
characteristics into normal brain tissue. Individual cells can be found several millimeters 
away from the tumor margin and show several of the ‘secondary structures of Scherer’: 
perineuronal satellitosis, perivascular satellitosis, subpial spread and incasion along the white 
matter tracts219,220. They also show areas of pseudo-palisading necrosis, similar to human 
GBM and express human GBM markers such as GFAP and S100216. The GL261 mouse 
model also shares some genetic mutations with human GBM, for example point mutations in 
the K-Ras and p53 genes221,222 as well as increased activation of the PI3K pathway223.  
Due to its resemblance to the human disease, not only in cellular composition and 
invasiveness but also in tumor aggressiveness, the GL261 model is a good choice to study 
immune components of GBM and potential immunotherapeutic approaches. I used the 
GL261 model in Paper III to study the immune cell composition of the tumor and target 
different cell types with depletion techniques. 
 
2.4 B16 MELANOMA MODEL 
As for GBM, also in melanoma the advantage of using a syngeneic transplantation model is 
that the animals are immunocompetent, which allows melanoma cells to interact with T-cells 
and B-cells naturally, as they do in the human melanoma microenvironment224. The B16 
melanoma cell line is the most widely used cell line, especially in the study of immune-tumor 
interactions and immune therapeutics. The cell line was chemically induced to produce 
spontaneous tumors.  
Figure 4: Efficient depletion of microglia followed by repopulation using the Cx3cr1CreER-R26DTA mouse model. 
P2ry12 (green, microglia specific), CX3CR1-YFP (red), overlap (yellow). 
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Two main clones are commonly used, B16F1, which has low metastatic potential and is used 
to study primary tumors and B16F10, which has a high metastatic potential to distant visceral 
organs225,226. The B16 model differs vastly from the human disease in genetic mutations, 
most notably for Braf. While the human disease has at least 60% of tumors mutated in BRAF, 
the mouse model only exhibits minor mutations in this gene227. PTEN, another commonly 
mutated gene in human disease, is not usually mutated in B16 cells227. Another factor that has 
to be considered when using this melanoma model is that B16 cells proliferate fast, making 
long-term studies virtually impossible due to ethical considerations228. As with every other 
animal model there is skepticism towards the validity of the model when comparing to the 
human situation, but for basic studies the B16 syngeneic mouse model is suitable229. I used 
the B16 melanoma mouse model to study the effect of siRNA delivered by nanoparticles in 
Paper IV. 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I: COMPETITIVE REPOPULATION OF AN EMPTY MICROGLIAL 
NICHE GIVES RISE TO FUNCTIONALLY DISTINCT SUBSETS OF 
MICROGLIA-LIKE CELLS 
In paper I we developed a new model for microglia depletion by breeding Cx3cr1CreER mice 
with R26DTA mice. By doing so, microglia are efficiently depleted by more than 95% within 7 
days upon Tamoxifen administration to the adult offspring. As in all other depletion models, 
be it pharmaceutically or genetically, the microglia niche becomes repopulated within 14 
days after depletion. This does not make our model unique per se, but that repopulation 
occurs not only from the naïve microglia pool through proliferation but in addition through 
infiltration of Ly6Chi monocytes from the periphery into the brain is indeed novel in our 
model, and opens up new possibilities to research cell replacement therapies. To date, 
microglial turnover (in steady state) or repopulation (upon depletion) was only reported to 
occur either through microglial proliferation70,104,107,230,231 or through infiltration of 
peripherally derived myeloid cells61,66,69,100,232,233, but not to occur simultaneously.  
Aim: 
To develop an efficient long-term microglia depletion model in order to study niche 
competition. 
Background: 
Circulating monocytes can compete for any tissue macrophage niche and become long-
lived replacements that are phenotypically indistinguishable from their embryonic 
counterparts under specific conditions. Factors regulating this process are not well 
understood.  
Hypothesis: 
Microglia can be efficiently depleted followed by repopulation by different sources 
without affecting health and cognitive functions in mice.  
Results: 
Cx3cr1CreER-R26DTA mice are depleted of microglia by >95% after Tamoxifen treatment. 
Within weeks the microglial niche is repopulated by a combination of local proliferation 
of CX3CR1+F4/80low microglia and infiltration of CX3CR1+F4/80hi macrophages. 
Infiltrating macrophages arise directly from Ly6Chi monocytes entering the brain from the 
periphery. This colonization by monocytes is independent of blood brain barrier 
disruption, does not require progenitor cells, is accompanied by vascular activation and 
regulated by type I interferon.  
Ly6Chi monocytes upregulate microglia-specific gene expression and adopt a microglial 
DNA methylation profile, but still retain a distinct gene expression profile. Our results 
demonstrate that monocytes can be imprinted by the CNS microenvironment but remain 
functionally, epigenetically and transcriptionally distinct cells. 
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In addition, most studies reporting engraftment of peripheral cells in the brain were 
performed in models in which damage to the BBB cannot be excluded69,70,100,104,233, leading to 
the conclusion that it is an experimental artefact. In our model, however, we prove that the 
BBB is undisrupted and infiltration by peripheral myeloid cells into the CNS still occurs, 
which supports previous findings by Cronk et al.232. 
In this discussion I try to shed some light on past and recent publications of microglial 
depletion and repopulation studies, and their differences as well as similarities to our own 
findings in Paper I. 
Disruption of the Blood Brain Barrier: 
BBB disruption following whole body irradiation is considered as one of the major factors for 
infiltration of peripheral myeloid cells into the parenchyma. Ajami et al. reported in 2007 that 
local microglia proliferation sustains the CNS microglia population in the adult, whereas 
infiltration of peripheral bone marrow cells is possible upon lethal irradiation of the mouse70. 
Similarly, in the Cx3cr1CreER-R26DTR depletion mouse model, Bruttger et al. reported that 
microglia are only repopulated from the periphery after depletion when the mice are lethally 
irradiated without head protection, and become reconstituted with new bone marrow-derived 
cells104. Both studies attribute this infiltration to damage of the BBB as a result of irradiation. 
In contrast, a paper published in 2012 very convincingly reported that lethal irradiation using 
10Gy does not affect the integrity of the BBB234, as measured by IgG and albumin content in 
the brain upon whole body irradiation. Damage to the BBB was reported in earlier studies, 
but higher doses (20-50Gy) were used in those235, leading to the conclusion that disruption of 
the BBB only happens at high doses of irradiation. 
In further support of our finding that disruption of the BBB is not necessary for peripheral 
cells to enter the brain is the report by Cronk et al. who showed that chronic depletion of 
microglia in a Cx3cr1CreER-CSF1Rfl/fl mouse model by feeding Tamoxifen chow also leads to 
repopulation of the microglial niche by infiltrating cells232. However, BBB damage and cell 
infiltration can indeed be an experimental artifact in the CD11b-HSVTK microglial depletion 
model, where insertion of an intracerebroventricula cannula is necessary for constant 
ganciclovir administration100, but no experimental data was provided to prove disruption of 
the BBB. 
Inflammation in the Brain upon Microglia Depletion: 
Increased astrocyte activation and pro-inflammatory cytokine expression in the brain was 
evident after depletion of microglia in our Cx3cr1CreER-R26DTA model, which was largely 
resolved after two weeks. Other studies reported short-term inflammation of the brain 
following depletion, which is most likely attributable to massive microglial death in the 
tissue. For example, Bruttger et al. reported that inflammatory cytokines are enhanced in their 
Cx3cr1CreER-R26DTR model in which 80% of microglia are depleted, but no infiltration of 
peripheral cells occurs during repopulation104.  
Cronk et al. demonstrated that a chronic depletion of 25% of the microglial pool is sufficient 
to trigger peripheral myeloid cell infiltration232.  
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Even though inflammation seems to be a common effect in various different depletion 
models, inflammation alone is therefore most likely not the reason why bone marrow cells 
infiltrate the brain and permanently engraft there. 
Introduction of Stem Cells into the Circulation: 
Ajami et al. reported that during homeostasis microglia sustain their pool by local 
proliferation and that peripheral cells only contribute if the BBB is disrupted and cells are 
transplanted. By irradiating one partner of a parabiotic pair and not irradiating the other, they 
demonstrated that irradiation and BBB disruption alone was not sufficient for peripheral cells 
to contribute to the microglia pool, but that cell transplantation is needed for this to happen70. 
A subsequent report indicated that infiltration of the brain occurs through precursor/stem cells 
that are released into the blood in increased amounts upon irradiation without passing through 
a monocyte intermediate. This finding was supported by Bruttger et al. who used an anti-
CCR2 antibody to demonstrate that infiltration following irradiation is not affected upon 
depletion of CCR2+ monocytes in the circulation104. In contrast, we show that Ly6ChiCCR2+ 
monocytes infiltrate the CNS, which further permanently engraft in the CNS using adoptive 
transfer of purified Ly6Chi CCR2+ monocytes in Paper I. Our findings were confirmed by 
Mildner et al. who identified Ly6ChiCCR2+ monocytes as direct ‘precursors’ of microglia 
also by using bone marrow chimeras and adoptive transfer models. Mice lacking 
Ly6ChiCCR2+ monocytes did not exhibit any engraftment into the brain69. In further support 
of monocytes being microglia ‘precursors’ Cronk et al. also reported stable Ly6ChiCCR2+ 
monocyte engraftment upon adoptive transfer232 in parabiotic mice.  
Impairment of Microglia Proliferation: 
Even though local microglia proliferation partly reconstitutes the empty microglia niche in 
our model it is not efficient enough to fill the entire niche, and hence infiltrating cells are 
recruited. Our conclusion is that the proliferative ability of microglia is compromised in our 
model. In support of this are the findings of the chronic microglia depletion model used by 
Cronk et al.. Conversely, in clear opposition to these findings, CSF1R inhibitor-treated mice, 
in which 99% of microglia are depleted, do not exhibit any signs of peripheral input, but 
instead repopulate the niche through extensive proliferation of the surviving microglia231,236. 
CSF1R treatment very likely also inhibits monocytes from repopulating the brain. Also in 
contrast to our findings, Cx3Cr1CreER-R26DTR recover by microglial numbers within days 
through hyperproliferation131.  
In conclusion, factors influencing engraftment of peripheral cells in the brain and local 
microglial proliferation need to be studied further in order to draw conclusions and use these 
models for cell replacement therapies. In addition to establishing a new model of microglial 
depletion in which repopulation of the niche occurs without BBB disruption and without 
input from stem cells, we were further able to identify microglia and ‘bone marrow-derived’ 
microglia-specific genes, making it possible to distinguish them.  
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Cronk et al. also defined core signatures of brain engrafting macrophages (beMƟ-50) and 
microglia (Mg-52)232, largely overlapping with our own dataset, which strongly supports our 
data. Two other recent publications shed additional light on this issue. In support of our data, 
graft-derived macrophages acquired microglia characteristics over time, including ramified 
morphology, longevity, radio-resistance and clonal expansion, but even after prolonged CNS 
engraftment yolk sac-derived host microglia and BM-derived macrophage transcriptomes and 
chromatin accessibility landscapes remained distinct237. Furthermore, they reported a 
strikingly similar gene signature of microglia and BM-derived cells when compared to our 
own data. As in our study, expression of Ms4a7 and Clec12a were reported as being BM 
engrafted cell-specific, whereas P2ry12, Sall1 and Sall3 are only expressed by host microglia 
even after prolonged integration of BM cells into the parenchyma. The differences in gene 
expression signatures were partly explained due to the absence of Sall1 in donor cells, whose 
transcriptome overlapped significantly with that of Sall1-deficient microglia.  
Similarly, transplantation studies were used to elucidate similarities and differences between 
host microglia and BM-derived cells238. Even though proper engraftment of donor cells from 
yolk sac, fetal liver and bone marrow origin were all observed, only yolk sac microglia-like 
cells expressed a microglia-specific gene signature whereas other cells (fetal liver derived, 
BM derived) showed similar gene expression to microglia but failed to become ‘true’ 
microglia. P2ry12237 and Ms4a7238 were also identified in human tissue as being microglia- 
and donor cell-specific, respectively, and thus studies of microglia replacement therapies on 
human tissue will be facilitated by use of these markers. 
All-in-all, peripheral infiltration can occur even under homeostatic conditions, but the exact 
factors need to be further elucidated. A combination of all of the above is likely to occur, 
depending on the model or disease setting. The brain is a highly dynamic organ and it is 
likely that there is not only one true explanation of when and how peripheral repopulation 
occurs or when microglia are able to fill an empty niche through hyper-proliferation. 
  
Figure 5: Graphical representation of microglia depletion and repopulation. 7 days after Tamoxifen treatment microglia are 
depleted >95%. Within 28 days the microglia niche is repopulated by proliferation of resident microglia (F4/80lo, pink) and 
infiltration of Ly6Chi monocytes from the periphery (F4/80hi, grey). 
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3.2 PAPER II: FATAL DEMYELINATING DISEASE IS INDUCED BY 
MONOCYTE-DERIVED MACROPHAGES IN THE ABSENCE OF TGF-Β 
SIGNALING 
In paper II we used findings of paper I to elucidate the role of TGF-β signaling in brain- 
engrafting macrophages. TGF-β signaling was identified as one of the major regulators of 
various genes identified in the two different populations of microglia (F4/80low) and brain 
macrophages (F4/80high). Tgfβr1 expression in repopulated cell populations was comparable 
to naïve microglia, whereas it was almost absent in Ly6Chi monocytes. Upregulation of 
Tgfβr1 expression upon infiltration into the brain itself hence suggests an important role of 
TGF-β signaling in brain-engrafting macrophages and microglia. In addition, TGF-β 
signaling was previously identified to be crucial for the development and maintenance of 
microglia using RNA-sequencing and functional studies239.  
To address whether TGF-β signaling is crucial for peripheral monocytes to be recruited to the 
brain, we used bone marrow chimeras in which we reconstituted irradiated Cx3cr1CreER-
R26DTA mice with LysMCre/+Tgfβr2fl/fl bone marrow. Upon depletion, monocytes lacking TGF-
β signaling failed to migrate to the brain or were not able to populate the niche and compete 
with monocytes with intact TGF-β signaling, hinting towards a crucial role of TGF-β in 
repopulating-engrafting monocytes. We then investigated what happens when TGF-β 
signaling is disrupted after monocytes passed the BBB and entered the parenchyma.  
Aim: 
To study the role of TGF-β in microglia niche repopulation by peripheral cells. 
Background: 
TGF-β regulates the development and homeostasis of several tissue resident macrophage 
populations, including microglia. Even though TGF-β is not critical for microglial 
survival, it is required for the maintenance of the microglia-specific homeostatic gene 
signature.  
Hypothesis: 
TGF-β signaling is crucial for niche homeostasis and required for monocyte-derived 
macrophage integration into the niche. 
Results: 
Upon deletion of TGF-β signaling in CX3CR1+ monocyte-derived macrophages in a 
setting of CNS repopulation, mice develop a progressive and fatal demyelinating motor 
disease characterized by myelin-laden giant macrophages throughout the spinal cord and 
at the end stage in the brain. Tgfbr2-deficient macrophages showed high expression of 
genes encoding proteins for antigen presentation, inflammation and phagocytosis. TGF-β 
signaling is therefore crucial for the functional integration of monocytes into the CNS 
microglial niche. 
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We made use of the fact that upon crossing the BBB monocytes start upregulating certain 
microglia-specific genes, one of them being Cx3cr1. We made bone marrow chimeras, 
transferring Cx3cr1CreERTgfβr2fl/fl bone marrow into Cx3cr1CreER-R26DTA microglia depletion 
mice. Using this set up we were able to deplete microglia and delete Tgfβr2 in macrophages 
that crossed the BBB and upregulated CX3CR1 upon doing so. Surprisingly, mice developed 
a progressive and fatal demyelinating disease characterized by fore- and hind leg weakness, 
incontinence and complete paralysis at the end stage. Histological analysis of spinal cord and 
brain sections revealed that infiltrating macrophages start ‘attacking’ the spinal cord (and at 
the end stage of the disease the brain) and ingest myelin. Tgfβr2 deleted macrophages were 
transcriptionally characterized by upregulation of genes involved in antigen presentation, 
inflammation and phagocytosis. 
Butovsky et al. reported a crucial role of TGF-β signaling in microglia, where mice lacking 
TGF-β1 in the CNS have defects in extracellular glutamate homeostasis and synaptic 
plasticity and develop motor symptoms at 4-6 months of age, noticeable by a decreased body 
weight and reduced rotarod performance239. No pathological mechanism was reported, but 
the authors noted a loss of microglia in these mice in both the brain and the spinal cord. 
Applying our knowledge from Paper II, we can propose a pathological mechanism for 
Butovskys’ findings. 
It is not surprising that disruption of TGF-β signaling in microglia and infiltrating 
macrophages has devastating effects since it was previously reported that mice homozygous 
for a mutated TGF-β1 allele or TGF-β null develop multifocal inflammatory disease240 and 
die soon after birth241. Conversely, deleting Tgfβr2 in myeloid cells in the periphery enhances 
their anti-tumor abilities by increasing pro-inflammatory genes and antigen presentation 
genes 242, highlighting the importance and opposing roles of TGF-β signaling in many 
different diseases. In neurological diseases it was recently shown that TGF-β signaling is 
often reduced, including Alzheimer’s disease 243.  
Interestingly, our chimeric mice developed lesions always in the same anatomical regions, 
starting in the dorsal column of the spinal cord and in the end stage lesions in thalamus, 
whereas the ventral column of the spinal cord and the cerebrum appeared normal. Regional 
specificity has been reported in neurological diseases but the origins are still unknown. It 
would therefore be important to elucidate what determines this very specific demyelination 
pattern. One step towards answering this question was provided by Grabert et al. and Stevens 
et al. who reported that microglia express region-specific gene signatures244,245.  
In conclusion, TGF-β signaling is a central player for the recruitment of macrophages to the 
brain and their functional integration into the empty microglia niche. The failure to respond to 
TGF-β may explain the onset or progression of neurodegenerative and neurological diseases.  
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Figure 6: TGF-β regulates integration of monocytes into the empty microglia niche. TGF-β is needed to 
maintain homeostasis as well as repopulation by monocytes after depletion (grey). In the absence of TGF-β 
signaling, monocyte-derived macrophages (red) attack the tissue by ingesting myelin from axons of neurons 
(blue). 
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3.3 PAPER III: EOSINOPHIL DEPLETION AS A NOVEL TREATMENT IN A 
MOUSE MODEL OF GLIOBLASTOMA MULTIFORME 
 
In Paper III we studied immune cell infiltration in a mouse model of GBM. In support of the 
current literature246,247 we recorded a vast increase in macrophage/microglia number over the 
time of tumor growth, which led to our first hypothesis of using pro-inflammatory 
macrophages to counteract the immunosuppressive microenvironment of the tumor, leading 
to an immune reaction that limits tumor growth. Different targeting strategies to counteract 
TAMs have been proposed, from inhibition of macrophage recruitment to the 
tumor248,249,250,251, suppression of TAM survival252, enhancing tumoricidal activity of 
proinflammatory TAMs253 or blockage of tumor growth promoting activity of 
immunosuppressive TAMs254,255. 
Aim: 
To characterize immune cell infiltration in experimental GBM and identify novel 
targets for immunotherapy. 
Background: 
Glioblastoma multiforme (GBM) is a devastating brain tumor with a very short life 
expectancy after diagnosis. Treatment options are limited to chemotherapy, 
radiotherapy and surgery, all of which do not significantly prolong survival. Immune 
cells infiltrate the tumor, with macrophages and microglia reportedly being the major 
cells contributing to the tumor. Targeting macrophages has been proposed as a 
treatment but to date no therapy has yielded significant effects on survival.  
Hypothesis: 
Eosinophils contribute to tumor growth and depleting them will prolong survival.  
Results: 
Infiltrating monocytes and microglia were both significantly enriched in the tumor, as 
previously reported. Despite employing radical depletion models for monocyte and 
microglia depletion we could not significantly prolong survival in the GL261 model. 
We identified eosinophils as the major cell infiltrate in experimental GBM. Depleting 
eosinophils using an anti-IL-5 antibody significantly prolonged survival. Eosinophil 
infiltration was also observed in human GBM tissues, supporting our notion that 
targeting this usually neglected cell type might be of advantage in the treatment of 
GBM. 
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In a previous study, the Harris lab reported that adoptive transfer of ex vivo stimulated M2 
macrophages prevents Type 1 diabetes in mice256. We decided to use a similar approach to 
test our hypothesis, by stimulating macrophages ex vivo to a pro-inflammatory M1 phenotype 
and injecting them into the tumor vicinity. Injected macrophages were not able to survive and 
hence no anti-tumor effect was achieved using this approach.  
 
 
 
 
 
 
 
 
We therefore revised our approach and targeted monocytes and microglia by using genetic 
depletion models (CCR2-/- mice and Cx3cr1CreER-R26DTA mice established in Paper I). The 
targeting of single immune cell subsets (monocytes or microglia) only revealed a minimal 
effect on survival of tumor bearing mice, suggesting that a combination therapy might be a 
more effective approach for the treatment of GBM. Indeed, targeting CCR2 using antibody 
treatment by itself was reported to only modestly prolong survival, although significantly in 
mice. Combination treatment with TMZ increased the effect of CCR2 treatment249.   
Even though we observed significant monocyte/macrophage and microglia numbers in our 
GBM model, the most abundant cell type was eosinophils. Since targeting monocytes and 
microglia did not yield significant effects on survival we decided to revise our hypothesis and 
target eosinophils instead of focusing on macrophages. We identified stable eosinophil 
accumulation in mouse GBM as evidenced using both flow cytometry and 
immunohistochemistry. The signals attracting eosinophils to the brain tumor remain to be 
elucidated. It has been suggested that eosinophil migration is increased by 
immunosuppressive macrophages due to increased levels of IL-10 and hence increased 
production of CCL24 by these cells257. TAMs usually display an immunosuppressive 
phenotype and produce IL-10, supporting the idea that TAMs are responsible for eosinophil 
attraction to the tumor. 
Not only immunosuppressive TAMs can attract eosinophils by producing eosinophil 
chemoattractants, but also signals released from areas of necrosis in the tumor were reported 
to attract eosinophils117. Both mechanisms could provide an explanation for eosinophil 
recruitment to the tumor in our model. CCR3 staining of tumor brain tissues revealed 
eosinophilic degranulation in necrotic parts of the tumor.  
Figure 7: Injection of 150,000 YFP+ macrophages into the brain parenchyma. Only a 
minimal number of M1 macrophages survive upon injection into the tumor vicinity in the 
brain parenchyma, and no tumoricidal effect was noted. 
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This could indicate that eosinophils actively try to attack the tumor to a certain extent, but 
ultimately fail to be effective in this process. 
Using an anti-IL-5 antibody (TRFK5)131 we were able to significantly prolong survival of 
tumor bearing mice. Treatment with TRFK5 inhibits eosinophil release from the bone 
marrow into the circulation, but eosinophils already in the circulation are not affected. This 
could be the explanation why a small number of eosinophils is still present in the tumor, even 
after depletion. Again, a combination of different antibodies should be considered to achieve 
a more significant effect on survival. 
In human GBM, eosinophil accumulation has so far only been attributed to peri-tumoral 
edemas, and to our knowledge have not been shown to accumulate in bulk tumor tissue. 
Dexamethasone, a corticosteroid, is commonly used for the treatment of asthma to prevent 
eosinophil infiltration into the lungs. It is also implicated in the treatment of peri-tumoral 
edemas in GBM, which led to reduced tumor size as evidenced by contrast enhanced scans in 
some cases. This effect is attributed to blockage of GM-CSF release from T-cells by 
dexamethasone, which decreases survival of GM-CSF-dependent eosinophils258. Increase of 
eosinophil death and consequent release of their cytotoxic granule proteins leads to a short-
term reduction in tumor size in GBM patients259,260,261.  
Supportive of our data are several studies of expression of eosinophil chemoattractants and 
their receptors in human GBM262, but no studies to date have been performed on eosinophil 
infiltration into the tumor mass. 
In conclusion, we demonstrate a stable eosinophil infiltration in a mouse model of GBM over 
the time of tumor growth, as well as human GBM tissue, evidenced by 
immunohistochemistry. The exact mechanism of eosinophil infiltration into the tumor 
remains to be investigated. We thus suggest that targeting eosinophils directly in GBM 
patients by blocking eosinophil development or chemotaxis could increase survival and 
lessen tumor burden. 
Figure 8: IL-5 is crucial for eosinophil emigration from the bone marrow into the circulation. From the blood, eosinophils travel to 
the brain and associate with the tumor (grey), due to so far unknown factors. Treatment with anti-IL-5 antibody inhibits eosinophil 
emigration from the bone marrow, leading to less eosinophil infiltration in the tumor and hence longer survival.  
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3.4 PAPER IV: ASSESSMENT OF NANOPARTICLE SIRNA DELIVERY IN 
VITRO AND IN VIVO FOR THE TREATMENT OF TUMORS IN MOUSE 
MODELS OF MELANOMA AND GLIOBLASTOMA MULTIFORME 
Since injecting pro-inflammatory M1 macrophages was not successful due to space 
restrictions and death of the cells, we aimed for a different approach to modulate the tumor 
microenvironment in Paper IV.  
Therapies based on RNA interference (RNAi) have been shown to be a powerful method for 
inhibiting disease targets from any molecular class and numerous proof-of-concept studies 
have been performed and been successful in various different diseases263. siRNAs are 
macromolecules that need to be delivered to the cellular machinery responsible for mRNA 
degradation to be effective, but so far there are problems of non-specific accumulation in 
tissues, poor cellular uptake or inefficient release of siRNA into the cytoplasm264. One of the 
major challenges is therefore successful and targeted drug delivery, to make siRNA drugs 
more potent and to avoid side-effects.  In Paper IV, we worked with different nanoparticle 
(NP) formulations to package siRNA for the treatment of melanoma, and at later stages 
Glioblastoma multiforme. 
Aim: 
To prove the principle of siRNA delivery via nanoparticles for treatment of 
experimental melanoma and GBM.  
Background: 
Delivery of siRNA molecules has proven to be difficult due to unspecific release of 
siRNA and accumulation in tissues.  
Hypothesis: 
siRNA-loaded nanoparticles can be used to more directly and efficiently target tumor 
cells and tumor associated immune cells with less adverse effects on healthy tissue. 
Results: 
We assessed the efficacy of si-TGFβ1, si-IL10 and si-TGFβR2 in either chloroquine- 
containing nanoparticles or β-glucan encapsulated yeast particles (GeRPs) to modulate 
macrophage activation in vitro as well as the effect on tumor growth in vivo. All 
targets could be significantly down-regulated using siRNA, alone or in combination. 
GeRPs were readily detectable in vitro and in vivo using flow cytometry and 
immunohistochemical approaches. Preliminary in vivo data showed promising 
retardation of tumor growth using chloroquine-siRNA-HA particles in a mouse model 
of melanoma, making both types of nanoparticles promising new technologies for 
future cancer treatments. 
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TGF-β1 and Tgfβr2 as Targets for siRNA: 
TGF-β signaling is involved in many different processes, having crucial roles in 
development, homeostasis and disease. TGF-β signaling downregulation in myeloid cells has 
been reported to reduce tumor burden in mice242,265,266, and hence this signaling pathway is 
ideal to target for proof-of-concept studies and to determine delivery efficiency of siRNA by 
nanoparticles. Efficient downregulation of TGF-β1 was achieved in vitro in BMDM, B16 
melanoma cells and in vivo in melanoma tumors, and in vitro for Tgfβr2 in BMDM. 
Downregulation of TGF-β1 was accompanied with less tumor burden in mice. 
GeRPs: 
Glucan nanoparticles were specifically developed to target phagocytic cells, mainly 
macrophages264. The -glucan facilitates specific binding to macrophage-expressed CLEC 
receptors, thereby ensuring specific delivery to macrophages and not to other immune cells. 
Following phagocytosis, glucan particles reach acidified endosomes, leading to release of 
their siRNA into the cytoplasm and allowing specific gene silencing. Previous studies 
demonstrated that these particles effectively deliver siRNA to various tissue macrophages and 
that they were effective for the treatment of Diabetes267, but have so far not been tested in 
tumor models. Targeting TAMs instead of tumor cells directly was proposed to be a feasible 
therapeutic approach due to the vast number of TAMs apparent in solid tumors268. 
We confirmed uptake of GeRPs into bone marrow-derived macrophages (BMDM) and 
efficient downregulation of our target genes. In addition, in vivo uptake was confirmed by 
injection of FITC-labelled GeRPs into the brain parenchyma. FITC signal could be detected 
for at least 72h after GeRP injection into the brain. Due to its isolated location the brain is 
ideal for tracing experiments. In addition, trauma caused by the needle leads to macrophage 
infiltration into the brain. These infiltrating macrophages usually exhibit M1 phenotypes and 
can be distinguished from microglia by their higher CD45 expression. Infiltrating 
macrophages phagocytosed significantly more GeRPs than did microglia in the brain at the 
24h time point, confirming our in vitro phagocytosis assay results in which M1 polarized 
BMDM were better in phagocytosing GeRP than were M2 cells. This can be explained by the 
fact that infiltrating macrophages express high levels of Clec-2214, a member of the Dectin-1 
family of receptors that is responsible for uptake of -glucan269,270. This is important to 
consider for further in vivo studies in tumor models, since TAMs usually exhibit a M2 
phenotype.  
CQ-siRNA-HA, Dox-siRNA-HADA: 
Activation of the innate and adaptive immune systems by complement activation triggered by 
opsonin binding, is considered as one of the major obstacles with nanoparticle 
formulations271. As a second class of nanoparticles we used CQ-siRNA-HA and Dox-siRNA-
HADA particles. Hyaluronic acid (HA) is a natural polymer derived from the extracellular 
matrix (ECM) that offers great benefits in engineering NPs owing to their unique 
biocompatibility, cell surface CD44 receptor targeting ability and non-toxic degradation 
profiles.  
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The CD44 targeting ability of HA makes it ideal for developing NPs for anti-cancer therapies, 
as CD44 receptors are over-expressed in several solid tumors (≈4–5-fold), including 
glioblastoma multiforme (GBM)272,273.  
In addition to HA, chloroquine in these particles facilitates a modulation of intracellular pH in 
myeloid cells, which improves the efficiency of tumor immunotherapy274. 
The intrinsic anti-tumor activities of chloroquine by enhancing an M1 phenotype in TAMs, in 
addition to siRNA delivery to TAMs as well as tumor cells, makes the CQ-siRNA-HA 
particles a powerful tool for cancer therapy. In a first trial experiment we could significantly 
reduce tumor burden in B16 melanoma-bearing mice.  
In conclusion, Paper IV is a proof-of-concept study determining the efficiency of siRNA 
delivery by nanoparticles of different formulations. CQ-siRNA-HA particles showed 
promising results in a first in vivo trial, and it has to be elucidated whether GeRPs can be as 
effective considering they only target TAMs in the tumor and not, as CQ-siRNA-HA 
particles, TAMs and tumor cells at the same time. In addition, even though TGF-β1 was 
efficiently downregulated in the tumors, treated mice still had quite big tumors, leading to the 
conclusion that targeting only one gene will not be sufficient to eradicate the tumor. Hence, 
as already discussed for Paper III, a combination of targets will most likely be needed to not 
only reduce tumor growth but to completely eradicate the tumors. 
 
 
 
  
Figure 9: The tumor is surrounded by an immunosuppressive microenvironment (blue), keeping immune cells from targeting the 
tumor (grey). siRNA-loaded nanoparticles (green) against TGF-β or other immunosuppressive cytokines can re-program the tumor 
microenvironment, leading to an effective immune response and retarded tumor growth. 
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